Compare TMP & OGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | TMP | OGN |
|---|---|---|
| Founded | 1836 | 1923 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.5B |
| IPO Year | 1996 | 2020 |
| Metric | TMP | OGN |
|---|---|---|
| Price | $100.99 | $13.72 |
| Analyst Decision | Hold | Hold |
| Analyst Count | 1 | 5 |
| Target Price | ★ $87.00 | $11.40 |
| AVG Volume (30 Days) | 83.7K | ★ 2.6M |
| Earning Date | 04-24-2026 | 05-07-2026 |
| Dividend Yield | ★ 3.21% | 0.60% |
| EPS Growth | ★ 126.16 | N/A |
| EPS | ★ 3.86 | 0.95 |
| Revenue | $75,742,000.00 | ★ $6,216,000,000.00 |
| Revenue This Year | N/A | $0.45 |
| Revenue Next Year | $7.94 | $1.67 |
| P/E Ratio | $25.99 | ★ $14.38 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $61.88 | $5.69 |
| 52 Week High | $102.02 | $13.70 |
| Indicator | TMP | OGN |
|---|---|---|
| Relative Strength Index (RSI) | 61.77 | 76.11 |
| Support Level | $91.10 | $13.46 |
| Resistance Level | $102.02 | N/A |
| Average True Range (ATR) | 2.27 | 0.04 |
| MACD | -0.17 | 0.01 |
| Stochastic Oscillator | 81.69 | 97.62 |
Tompkins Financial Corp is a Financial Holding Company. The company manages its operations through two business segments, consisting of banking and wealth management. It offers various products and services, including commercial and consumer banking, leasing, trust and investment management, financial planning and wealth management, and insurance. Wealth management activities include the results of the company's trust, financial planning, and wealth management services. The company generates the majority of its revenue from the Banking segment.
Organon & Cois a globalised healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day. Its operations include the following product portfolios: Women's Health: Itbwomen's health portfolio of products is sold by prescription mainly in two therapeutic areas: contraception, with key brands such as Nexplanon, and fertility, with key brands such as Follistim. other women's health products include the Jada, which is intended to provide control and treatment of abnormal postpartum uterine bleeding or hemorrhage when conservative management is warranted. The General Medicines portfolio includes biosimilars and established brands. Companies' current biosimilars portfolio spans across immunology and oncology-related treatments.